Formulation Development Forum: Programmable, Wirelessly Controlled Microchips for Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation Development Forum: Programmable, Wirelessly Controlled Microchips for Drug Delivery
Wirelessly controlled microchips may offer an alternative to injection-based drug delivery


Pharmaceutical Technology
Volume 36, Issue 3, pp. 54

Patient compliance is important when developing a drug-delivery system, particularly when treating chronic diseases that require daily administration. Researchers at the Massachusetts Institute of Technology (MIT) recently reported on an alternative to daily injections: a programmable, wirelessly controlled microchip with an implantable device that allows drugs to be released inside the body without percutaneous connections in or on the patient. An implantable microchip device also offers the potential for real-time dose schedule-tracking and for physicians to remotely adjust treatment schedules.

The MIT researchers reported positive results of a human clinical trial using such a device. The primary objective of the rial was to assess the pharmacokinetics (PK) of the released drug, teriparatide, from the implanted devices. Safety measures included evaluating the biological response to the implant and monitoring indicators of toxicity. Secondary objectives were to assess the bioactivity of the drug and to evaluate the reliability and reproducibility of releasing the drug from the device.

In the trial, human teriparatide, a parathyroid hormone fragment [hPTH(1-34)] and anabolic osteoporosis treatment, was delivered from the device in vivo. The microchip-based devices contained discrete doses of lyophilized hPTH(1-34) and were implanted in eight osteoporotic postmenopausal women for four months and wirelessly programmed to release doses from the device once daily for up to 20 days. A computer-based programmer, operating in the Medical Implant Communications Service band, established a bidirectional wireless communication link with the implant to program the dosing schedule and receive implant status confirming proper operation. Each woman subsequently received hPTH(1-34) injections in escalating doses (1). The human trial began in Denmark in January 2011. The chips used in the study stored 20 doses of teriparatide, individually sealed in reservoirs capped with a thin layer of platinum and titanium that melted when a small electric current was applied, thereby releasing the drug.

The device and drug combination were found to be biocompatible with no adverse immune reaction. The resulting PK profiles from the implant were comparable to and had less variation than the PK profiles of multiple, recommended subcutaneous injections of teriparatide. The study also demonstrated that the programmable implant was able to deliver the drug at scheduled intervals. Drug delivery and evaluation in patients occurred over a one-month period and provided proof-of-concept measures of drug release and device durability that support implantable device viability for 12 months or more, according to a Feb. 16, 2012, press release of MicroCHIPS, which has licensed the technology from MIT. The MIT researchers began work on the implantable chip in the 1990s (2).

The microchip-based implants can sense biochemical changes, deliver drug therapies, and wirelessly communicate status to networked patients and clinicians. The technologies use microreservoir arrays to hermetically store and protect pharmaceuticals or sensors for extended periods of time. The microchip is controlled by microprocessors, wireless communications, or sensor feedback loops for dynamic control of drug delivery or sensing. MicroCHIPS is developing new designs of its microchip-based implant to include as many as 400 doses per device for providing daily dosing for one year or multiyear therapy for less frequent dosing regimens.

Sources

1. R. Farra et al., Sci. Transl. Med. online, DOI: 10.1126/scitranslmed.3003276. Feb. 16, 2012.

2. J. Santini, M. Cima, and R. Langer, Nature 397 (6717), 335–338 (1999).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here